A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: Relationship between dose-intensity and efficacy. A phase II study

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 3087-3092

  Rossi, D ^a   Graziano, F ^b   Catalano, V ^a   Giordani, P ^a   Fedeli, S Luzi ^a   Alessandroni, P ^a   Fedeli, A ^a   Dennetta, D ^a   Ugolini, M ^a   Catalano, G ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

^b M Misericordia Hospital   (Italy)

Author keywords

Chemotherapy; Cisplatin; Dose intensity; Gemcitabine; NSCLC; Phase II study.

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; META ANALYSIS; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE;

EID: 0036765636     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
2. Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced nonsmall cell lung cancer: How much benefit is enough? J Clin Oncol 11(10): 1866-72, 1993.
3. Gatemeier U, Shepherd FA, Le Chevalier T et al.: Activity of gemcitabine in patients with non-small cell lung cancer: A Multicentre, extended phase II study. Eur J Cancer 32A: 243-48, 1996.
4. Peters GJ, Bergman AM, Ruiz Van Haperen W et al.: Interactions between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (suppl 14): 72-79, 1995.
5. Shepherd FA, Cormier Y, Burkes R et al.: Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24 (suppl 8): 27-30, 1997.
6. Crinò L, Scagliotti G, Marangolo M et al.: Cisplatin - gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15: 297-303, 1997.
7. Rinaldi M, Crinò L, Scagliotti GV et al.: A three week schedule of gemcitabine - cisplatin in advanced non-small cell lung cancer with two different cisplatin dose - levels: A phase II randomized trial. Ann Oncol 11: 1295-300, 2000.
8. Castellano D, Lianes P, Paz-Ares L et al.: A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9: 457-9, 1998.
9. Miller AB, Hoogstraten B, Staquet H et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
10. Cardenal F, Paz Lopez Cabrenizo M, Anton A et al.: Randomised phase III study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12-17, 1999.
11. Einhorn LH: Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier Oncology Group Study. Semin Oncol 24 (suppl 8): 24-26, 1997.
12. Crinò L, Scagliotti G, Ricci S et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: A randomised study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-30, 1999.
13. Shepherd FA, Auglin G, Abratt R et at.: Influence of gemcitabine (GEM) and cisplatin (CP) schedule on response and survival in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin OncoI 17: A814, 1998.
14. Shiller J, Harrington D, Sandler A et al.: A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 19: A la, 2000.
15. Sandler AB, Nemunaitis J, Denham C et al.: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 18: 122-130, 2000.
16. Vazquez F, Baron FJ, Cueva JF et al.: A cisplatin-gemcitabine phase II trial in locally-advanced and advanced non-small cell lung cancer. Annals of Oncology 9 (suppl 4): A 490, 1998.
17. Orlandi Jorquera L, Orlandi F, Galaz P et al.: Gemcitabine, plus cisplatin in advanced non-small cell lung cancer (NSCLC): a phase II trial. Ann Oncol 9 (suppl 4): A 486, 1998.
18. Sandler AB, Ansari I, Mc Clean J et al.: A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: A 1089, 1995.
19. Abratt RP, Bezwoda WR, Goedhals L et al.: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15: 744-49, 1997.
20. Steward WP, Dunlop DJ, Dabouis G et al.: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non small cell lung cancer: Preliminary result: Semin Oncol 23 (suppl 10): 43-47, 1996.
21. Cortesi E, Corona M, Gasperoni S et al.: Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Proc Am Soc Clin Oncol 18: A 1904, 1999.
22. Gonzalez-Baron M, Garcia M, Garcia Giron C et al.: Phase II activity of gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 18 (1): A 67, 1997.
23. Casal J, Huidobro G, Grande C et al.: Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC). Ann Oncol 9 (suppl 4): A 496, 1998.
24. Anton A, Artal A, Carrato A et al.: Gemcitabine plus cisplatin in advanced NSCLC: final phase II results. Proc Am Soc Clin Oncol 16: A 1656, 1997.
25. Gonzalez-Martin A, Garcia Lopez JL, Crespo, C et al.: A phase II study of a modified cisplatin and gemcitabine regimen in advanced non-small cell lung cancer (NSCLC): an ongoing study. Ann Oncol 9 (suppl 4): A 473, 1998.
26. Domine N, Casado V, Robles L et al.: Phase II study of cisplatin and gemcitabine (C-G) for advanced non small cell lung cancer (NSCLC): increasing dose-intensity and dose-density. Ann Oncol 9 (suppl 4): A 435P, 1998.
27. Mazzanti P, Del Prete S, Barrelli S et al.: Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin OncoI 18: A 1993, 1999.
28. Castellano D, Lianes P, Guerra JA et al.: Phase II study of gemcitabine and cisplatin every three weeks in patients with nonsmall cell lung cancer. Lung cancer 18 (1): A 100, 1997.
29. Cartei G, Sacco C, Cioschi B et al.: Gemcitabine and platin in advanced non-small cell lung cancer (NSCLC): a phase II study with emphasis on intention-to-treat analysis. Proc Am Soc Clin Oncol 17: A 1795, 1998.
30. Bergman AM, Ruiz Van Haperen VWT, Veerman G et al.: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-30, 1996.
31. Peters GJ, Bergman AM, Ruiz Van Haperen W et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (suppl 11): 72-79, 1995.